Author Archives: Marta Figueiredo

Problems With MRP4 Gene Raises Obesity Risk, Mouse Study Suggests

Suppressing the activity of a cellular transporter called multidrug resistance protein 4 (Mrp4) results in more fat tissue, less energy expenditure, and insulin resistance, according to a study in mice. These findings suggest that lower-than-normal Mrp4 levels can increase the risk of developing metabolic diseases such as obesity and type…

Rhythm Seeks to Test Setmelanotide in More Obesity Disorders This Year

Rhythm Pharmaceuticals has identified 31 additional genes whose mutations may be amenable to setmelanotide, its U.S.-approved therapy for genetic obesity disorders linked to the melanocortin-4 receptor (MC4R) pathway. This discovery is the result of Rhythm’s sequencing efforts and precision approach that has been recently validated in a Phase…

FDA-approved Setmelanotide Shows Promise in More Genetic Obesity Disorders

Three months of treatment with setmelanotide, an approved therapy for genetic obesity disorders, led to clinically meaningful body weight loss in adolescents and adults with additional diseases linked to the melanocortin-4 receptor (MC4R) pathway, data show. These interim data, from a Phase 2 basket trial, highlight setmelanotide’s potential…

Recent Posts